Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately ú420 million on August 7, 2022. The company will continue to be led by AlbumedixÆ Chief Executive Officer Jonas S. M°ller and its Executive Management team, who remain dedicated to servicing the life science industry. The transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022.

Milbank LLP provided legal counsel to Sartorius Stedim Biotech S.A in this transaction. William Blair acted as financial advisor to Albumedix,. Jon Cox-Brown and James Trevis of Eversheds Sutherland (US) LLP acted as legal advisor to Albumedix Ltd. BDO acted as Vendor Financial Due Diligence provider.